A-Share IPO Recap for July! 14 new stocks listed, with the highest single-lot profit reaching RMB 97,100. In July, a total of 14 new stocks were listed on the A-share market, an increase compared to June, bringing the year-to-date total to 85 new listings. The majority were from the Beijing Stock Exchange, accounting for over 60%, with two each on the ChiNext and STAR Market, and only one on the Main Board. The electronics sector led in the number of new listings, followed by industries such as machinery, automotive, pharmaceuticals, and beauty & personal care. The IPO subscription profitability was strong this month, with over 70% of new stocks more than doubling on their first trading day. Tolens surged 858.85%, leading all listings with a single-lot profit of RMB 97,100—the highest return of the month. Jihechang, Weiqi Shares, Changxin Technology, and Kangmeta all posted gains exceeding 400%, while Taino Medical rose over 200%. New stocks on the Shanghai and Shenzhen exchanges generally delivered higher single-lot returns, with several exceeding RMB 20,000. On the Beijing Stock Exchange, where each lot consists of 100 shares, only Weiqi Technology achieved a single-lot profit of RMB 13,300; the rest had relatively modest returns. Only two new stocks—Oulun Electric and Qiaoluming—had first-day gains below 50%, underperforming the market. Looking forward to August’s market performance.
0x鸣人Share

Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.